Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer

/Article comes from SAN DIEGO, May 14, 2018 /PRNewswire/ -- Immunicom, Inc., a medical technology company developing revolutionary non-pharmaceutical approaches for treating cancer and autoimmune diseases, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Immunopheresis™ therapy, which is based on a proprietary technology that selectively removes immune inhibitors from a patient's bloodstream potentially enabling their natural immune system to more-effectively attack cancer tumors. To achieve Breakthrough Device designation, a technology must demonstrate compelling potential to provide more effective treatment or

Last posts
Search by tags
Featured Posts